Infectious Disease Clinical Trials

Statistical methods in infectious disease trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All infectious disease trials

903 results

• IASISIndependent statistical analysis of Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 143NCT01969799
• Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis: Complete Statistical AnalysisIndependent statistical analysis of Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05399641).Phase 3Results postedn = 150NCT05399641
• Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 19NCT02997761
• ICIP-SAIndependent statistical analysis of Invasive Candidiasis in Saudi ICUs: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01490684).Phase NAResults postedn = 162NCT01490684
• IDEAIndependent statistical analysis of Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04425863).Phase NAResults postedn = 167NCT04425863
• IDEAL-ICUIndependent statistical analysis of IDEAL-ICU, a randomized phase 3 trial evaluating early versus delayed initiation of renal replacement therapy in ICU patients with septic shock and acute renal failure.Phase 3n = 500NCT01682590
• IMARA-SA pilotIndependent statistical analysis of A Comprehensive HIV Prevention Package for South African Adolescent Girls and Young Women: IMARA SA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 61NCT05504954
• Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions: Complete Statistical AnalysisIndependent statistical analysis of Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 91NCT02059499
• Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings: Complete Statistical AnalysisIndependent statistical analysis of Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 86NCT01446289
• Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10: Complete Statistical AnalysisIndependent statistical analysis of Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 186NCT04912297
• Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Mali: Complete Statistical AnalysisIndependent statistical analysis of Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Mali: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 218NCT00985465
• Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria: Complete Statistical AnalysisIndependent statistical analysis of Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 105NCT01153893
• Immunization To Prevent Acute COPD Exacerbations: Complete Statistical AnalysisIndependent statistical analysis of Immunization To Prevent Acute COPD Exacerbations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03276754).Phase NAResults postedn = 530NCT03276754
• Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 4Results postedn = 82NCT00610168
• Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 1,474NCT00197015
• Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 810NCT02752906
• Immunogenicity and Safety of a Purified Vero Rabies Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of a Purified Vero Rabies Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03145766).Phase 2Results postedn = 320NCT03145766
• Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 368NCT05116241
• Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060): Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060): primary endpoint results, effect…Phase 4Results postedn = 192NCT01926015
• Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1Results postedn = 40NCT01488188
• Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 341NCT01410474
• Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 131NCT01730378
• Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.: primary endpoint results, effect…Phase 2Results postedn = 572NCT03769194
• Immunogenicity and Safety Study of Booster Dose of GSK Biologicals’ IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 831NCT01449812
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals’ Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age: primary endpoint results,…Phase 3Results postedn = 692NCT01767376
• Immunogenicity and Safety Study of GSK Biologicals’ Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 1,013NCT01165242
• Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 4Results postedn = 15NCT01198769
• Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 440NCT01412281
• Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 85NCT01205581
• Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 3,851NCT00391053
• Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above: Complete Statistical AnalysisIndependent statistical analysis of Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above: primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 1,720NCT04732871
• Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 90NCT01943825
• Immunomodulatory Properties of Ketamine in Sepsis: Complete Statistical AnalysisIndependent statistical analysis of Immunomodulatory Properties of Ketamine in Sepsis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01089361).Phase 1/2Results postedn = 19NCT01089361
• Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions: Complete Statistical AnalysisIndependent statistical analysis of Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 1NCT03937791
• Impact of COVID-19 on Marshallese Communities in the U.S.: Complete Statistical AnalysisIndependent statistical analysis of Impact of COVID-19 on Marshallese Communities in the U.S.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04474496).Phase NAResults postedn = 120NCT04474496
• Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger: Complete Statistical AnalysisIndependent statistical analysis of Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 4Results postedn = 1,139NCT00618449
• IMPACT-TBIndependent statistical analysis of A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin: primary endpoint results, effect…Phase 2Results postedn = 24NCT03891901
• Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program: Complete Statistical AnalysisIndependent statistical analysis of Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 4Results postedn = 27NCT04650269
• Improving Cognitive Health in COVID-19 Survivors: Complete Statistical AnalysisIndependent statistical analysis of Improving Cognitive Health in COVID-19 Survivors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04843930).Phase 2Results postedn = 110NCT04843930
• Improving COVID-19 Vaccine Uptake in Nursing Homes: Complete Statistical AnalysisIndependent statistical analysis of Improving COVID-19 Vaccine Uptake in Nursing Homes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04732819).Phase NAResults postedn = 23,768NCT04732819
• Improving Treatment Adherence in HIV-Infected Individuals: Complete Statistical AnalysisIndependent statistical analysis of Improving Treatment Adherence in HIV-Infected Individuals: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00247611).Phase 2Results postedn = 594NCT00247611
• Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients: Complete Statistical AnalysisIndependent statistical analysis of Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 36NCT00871845
• Increasing Influenza and Tdap Vaccination of Pregnant Women: Complete Statistical AnalysisIndependent statistical analysis of Increasing Influenza and Tdap Vaccination of Pregnant Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04444518).Phase NAResults postedn = 12,760NCT04444518
• Increasing Optimal Use of HPV Vaccination in Primary Care: Complete Statistical AnalysisIndependent statistical analysis of Increasing Optimal Use of HPV Vaccination in Primary Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04180462).Phase NAResults postedn = 20NCT04180462
• INDUMAIndependent statistical analysis of Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00207142).Phase 4Results postedn = 252NCT00207142
• Inflammatory Cytokine Quantification in Infants: Complete Statistical AnalysisIndependent statistical analysis of Inflammatory Cytokine Quantification in Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01155830).Phase NAResults postedn = 21NCT01155830
• Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection: Complete Statistical AnalysisIndependent statistical analysis of Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 68NCT02716779
• Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain: Complete Statistical AnalysisIndependent statistical analysis of Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain: primary endpoint results, effect estimate with confidence…Phase 1Results postedn = 60NCT04978454
• Influenza Vaccine in Pregnant Women: Complete Statistical AnalysisIndependent statistical analysis of Influenza Vaccine in Pregnant Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00905125).Phase 2Results postedn = 102NCT00905125
• Influenza Vaccine Post Allogeneic Transplant: Complete Statistical AnalysisIndependent statistical analysis of Influenza Vaccine Post Allogeneic Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01215981).Phase NAResults postedn = 68NCT01215981

← All therapeutic areas